[
  {
    "ts": null,
    "headline": "Could GPL-1 weight loss soon come in pill form? What we know",
    "summary": "Eli Lilly, makers of weight loss injection Zepbound, could soon be making its GLP-1 drug in pill form.",
    "url": "https://finnhub.io/api/news?id=c96fd1762a9c7e6a3b6f492b252c3462a197ca0521ab2b7d3ab3aaa365a56d18",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754609114,
      "headline": "Could GPL-1 weight loss soon come in pill form? What we know",
      "id": 136266291,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly, makers of weight loss injection Zepbound, could soon be making its GLP-1 drug in pill form.",
      "url": "https://finnhub.io/api/news?id=c96fd1762a9c7e6a3b6f492b252c3462a197ca0521ab2b7d3ab3aaa365a56d18"
    }
  },
  {
    "ts": null,
    "headline": "Podcast: Nasdaq Hits Another High",
    "summary": "The Nasdaq composite hit a record high for the 17th time this year, ending up around 0.4%. Other U.S. stock indexes finished mixed as new tariffs took effect. Shares of Apple gained after the company announced an extra $100 billion investment in U.",
    "url": "https://finnhub.io/api/news?id=8cac3edb1903326715ecacea0ce94cc9817b668e5b5a3c77959f33da8632a355",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754607964,
      "headline": "Podcast: Nasdaq Hits Another High",
      "id": 136266292,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Nasdaq composite hit a record high for the 17th time this year, ending up around 0.4%. Other U.S. stock indexes finished mixed as new tariffs took effect. Shares of Apple gained after the company announced an extra $100 billion investment in U.",
      "url": "https://finnhub.io/api/news?id=8cac3edb1903326715ecacea0ce94cc9817b668e5b5a3c77959f33da8632a355"
    }
  },
  {
    "ts": null,
    "headline": "Markets Lose Momentum, Late Q2 Reports Move Stocks",
    "summary": "Indexes fell from their opening bell levels in the green across the board, with a slight surge late.",
    "url": "https://finnhub.io/api/news?id=f958f6b615008d2e28da83f89de91117350e472c62b3ab83375d36fbf9a3bcd5",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754605920,
      "headline": "Markets Lose Momentum, Late Q2 Reports Move Stocks",
      "id": 136266304,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Indexes fell from their opening bell levels in the green across the board, with a slight surge late.",
      "url": "https://finnhub.io/api/news?id=f958f6b615008d2e28da83f89de91117350e472c62b3ab83375d36fbf9a3bcd5"
    }
  },
  {
    "ts": null,
    "headline": "Dow, S&P 500 end lower; Eli Lilly shares fall after drug data",
    "summary": "STORY: U.S. stocks ended mixed on Thursday, with the Dow dropping about half a percent, the S&P 500 closing essentially flat, and the Nasdaq ticking up about three-tenths of a percent.Investors digested a Bloomberg report early in the session that Fed Governor Christopher Waller was President Donald Trump's top candidate for central bank chair.Trump has been highly critical of current Chair Jerome Powell for holding off on cutting interest rates as the Fed weighs the potential inflationary effects of Trump's tariffs.Higher tariffs on imports from dozens of countries kicked in on Thursday, raising the average import duty to its highest in a century. Adam Coons is chief investment officer at Winthrop Capital Management.“The other thing hitting markets today is the fact that tariffs kick in. And while we still have quite a bit of negotiating to do country by country, they are enacted. And so that is going to weigh on different aspects of the market, the supply chain, pricing. And so I think right now it's just, it's a lot of that digestion on, you know, how long are negotiations going to take for different countries? What will they look like in the end?”Stocks on the move Thursday included Eli Lilly, which plummeted more than 14% after data from its experimental weight-loss pill disappointed.Shares of cybersecurity firm Fortinet tumbled 22% after the company delivered a revenue forecast below Wall Street estimates.And shares of Pinterest climbed more than 12% in extended trading after the social media platform beat analysts' estimates for second-quarter revenue.Rapid growth among Gen Z users along with the platform's AI-powered marketing tools have made the company attractive to advertisers.",
    "url": "https://finnhub.io/api/news?id=5b45a140738a0999843d636ba38052962ef077703513d1962205a0c130cfc1f2",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754605029,
      "headline": "Dow, S&P 500 end lower; Eli Lilly shares fall after drug data",
      "id": 136266305,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "STORY: U.S. stocks ended mixed on Thursday, with the Dow dropping about half a percent, the S&P 500 closing essentially flat, and the Nasdaq ticking up about three-tenths of a percent.Investors digested a Bloomberg report early in the session that Fed Governor Christopher Waller was President Donald Trump's top candidate for central bank chair.Trump has been highly critical of current Chair Jerome Powell for holding off on cutting interest rates as the Fed weighs the potential inflationary effects of Trump's tariffs.Higher tariffs on imports from dozens of countries kicked in on Thursday, raising the average import duty to its highest in a century. Adam Coons is chief investment officer at Winthrop Capital Management.“The other thing hitting markets today is the fact that tariffs kick in. And while we still have quite a bit of negotiating to do country by country, they are enacted. And so that is going to weigh on different aspects of the market, the supply chain, pricing. And so I think right now it's just, it's a lot of that digestion on, you know, how long are negotiations going to take for different countries? What will they look like in the end?”Stocks on the move Thursday included Eli Lilly, which plummeted more than 14% after data from its experimental weight-loss pill disappointed.Shares of cybersecurity firm Fortinet tumbled 22% after the company delivered a revenue forecast below Wall Street estimates.And shares of Pinterest climbed more than 12% in extended trading after the social media platform beat analysts' estimates for second-quarter revenue.Rapid growth among Gen Z users along with the platform's AI-powered marketing tools have made the company attractive to advertisers.",
      "url": "https://finnhub.io/api/news?id=5b45a140738a0999843d636ba38052962ef077703513d1962205a0c130cfc1f2"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Sinks After Obesity Pill Shows Mixed Results",
    "summary": "Modest weight loss and side effects raise questions despite needle-free promise",
    "url": "https://finnhub.io/api/news?id=a6be056d6ce057aedb56f1b32c80ef7c4991b68eeb1a1f04d8b85dcf16d0cd33",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754603968,
      "headline": "Eli Lilly Sinks After Obesity Pill Shows Mixed Results",
      "id": 136266306,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Modest weight loss and side effects raise questions despite needle-free promise",
      "url": "https://finnhub.io/api/news?id=a6be056d6ce057aedb56f1b32c80ef7c4991b68eeb1a1f04d8b85dcf16d0cd33"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Roundup: Market Talk",
    "summary": "0804 GMT – Germany’s Merck KGaA reported second-quarter results that fell short of expectations at the top and bottom lines due to a weaker performance from the group’s electronics segment, Morgan Stanley analysts say in a research note.  The German life-sciences and chemicals group reported net sales that were 1% below consensus estimates, and Ebitda before exceptional items that missed forecasts by 4%, the analysts say.  Stronger expectations for Merck’s life-science and healthcare segments lead the group to raise its full-year guidance for organic growth in adjusted Ebitda, Morgan Stanley says.",
    "url": "https://finnhub.io/api/news?id=523850afccd8048462e9f06c94d7d358b5de2f900eb4cdfefe865b11cbc7cbb7",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754565240,
      "headline": "Health Care Roundup: Market Talk",
      "id": 136246277,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "0804 GMT – Germany’s Merck KGaA reported second-quarter results that fell short of expectations at the top and bottom lines due to a weaker performance from the group’s electronics segment, Morgan Stanley analysts say in a research note.  The German life-sciences and chemicals group reported net sales that were 1% below consensus estimates, and Ebitda before exceptional items that missed forecasts by 4%, the analysts say.  Stronger expectations for Merck’s life-science and healthcare segments lead the group to raise its full-year guidance for organic growth in adjusted Ebitda, Morgan Stanley says.",
      "url": "https://finnhub.io/api/news?id=523850afccd8048462e9f06c94d7d358b5de2f900eb4cdfefe865b11cbc7cbb7"
    }
  },
  {
    "ts": null,
    "headline": "Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025",
    "summary": "Baron Capitalâs Q2 report highlights biotech, surgical tech, and GLP-1 winners. Discover which health care stocks surged and what investors should watch next.",
    "url": "https://finnhub.io/api/news?id=0a3f18f4fd087a83164502be0872194a010302517a4e2dbfb87d9f212ec6b9f0",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754603100,
      "headline": "Baron Capital's Top Health Care Stock Picks And Misses From Q2 2025",
      "id": 136263799,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1359152753/image_1359152753.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Baron Capitalâs Q2 report highlights biotech, surgical tech, and GLP-1 winners. Discover which health care stocks surged and what investors should watch next.",
      "url": "https://finnhub.io/api/news?id=0a3f18f4fd087a83164502be0872194a010302517a4e2dbfb87d9f212ec6b9f0"
    }
  },
  {
    "ts": null,
    "headline": "S&P 500 Gains and Losses Today: Apple Stock Climbs; Eli Lilly Slumps After Disappointing Trial Results",
    "summary": "The S&P 500 slid 0.1% on Thursday, Aug. 7, 2025, as new tariffs took effect, raising import duties on goods from numerous U.S. trading partners.",
    "url": "https://finnhub.io/api/news?id=93c8069705b619910910891d87a9d565f295fefafa6589c5aee326ff82601e4c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754601789,
      "headline": "S&P 500 Gains and Losses Today: Apple Stock Climbs; Eli Lilly Slumps After Disappointing Trial Results",
      "id": 136266308,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The S&P 500 slid 0.1% on Thursday, Aug. 7, 2025, as new tariffs took effect, raising import duties on goods from numerous U.S. trading partners.",
      "url": "https://finnhub.io/api/news?id=93c8069705b619910910891d87a9d565f295fefafa6589c5aee326ff82601e4c"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Wavers as Tariffs Take Effect, Earnings Cycle Continues",
    "summary": "Equities closed mixed Thursday as President Donald Trump's new tariffs took effect, while traders pa",
    "url": "https://finnhub.io/api/news?id=f33663cc9ae7a8bb60161a8006acc98676dd43c757d5c48c95371d90efd356c1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754600816,
      "headline": "Wall Street Wavers as Tariffs Take Effect, Earnings Cycle Continues",
      "id": 136266309,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Equities closed mixed Thursday as President Donald Trump's new tariffs took effect, while traders pa",
      "url": "https://finnhub.io/api/news?id=f33663cc9ae7a8bb60161a8006acc98676dd43c757d5c48c95371d90efd356c1"
    }
  },
  {
    "ts": null,
    "headline": "Stocks to Watch Recap: Eli Lilly, Firefly, DoorDash, TSMC",
    "summary": "↗️ Apple (AAPL): The iPhone maker's shares rallied for a second day. Trump said companies could avoid 100% chip tariffs by investing in U.S. manufacturing. Apple unveiled an extra $100 billion commitment.",
    "url": "https://finnhub.io/api/news?id=3998bd74cfbd498dddb2544907b0b45323b4adf56acc35b198b073c95d3ac3b1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754599230,
      "headline": "Stocks to Watch Recap: Eli Lilly, Firefly, DoorDash, TSMC",
      "id": 136266310,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "↗️ Apple (AAPL): The iPhone maker's shares rallied for a second day. Trump said companies could avoid 100% chip tariffs by investing in U.S. manufacturing. Apple unveiled an extra $100 billion commitment.",
      "url": "https://finnhub.io/api/news?id=3998bd74cfbd498dddb2544907b0b45323b4adf56acc35b198b073c95d3ac3b1"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Moved the Most Today: Eli Lilly, Fortinet, AppLovin, Sunrun, Airbnb, Duolingo, and More",
    "summary": "A slew or company results were causing big market moves ahead of the opening bell Thursday, and for many, earnings-beat wasn’t enough to prevent a selloff.",
    "url": "https://finnhub.io/api/news?id=8437f05f425368be32854f1dbd9f62e12f5e8bbe8726916d3cd20c8756629c6b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754598480,
      "headline": "These Stocks Moved the Most Today: Eli Lilly, Fortinet, AppLovin, Sunrun, Airbnb, Duolingo, and More",
      "id": 136266311,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A slew or company results were causing big market moves ahead of the opening bell Thursday, and for many, earnings-beat wasn’t enough to prevent a selloff.",
      "url": "https://finnhub.io/api/news?id=8437f05f425368be32854f1dbd9f62e12f5e8bbe8726916d3cd20c8756629c6b"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Dives 14% On A Shocking Obesity Setback, Sending Its Rivals Flying",
    "summary": "Eli Lilly stock tumbled Thursday on an unexpected setback for its obesity franchise, sending shares of its rival flying.",
    "url": "https://finnhub.io/api/news?id=caecb6949683ec8e92e01bbf681ed85e9db57d8a20394ddadc05e5862b7d3724",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754576373,
      "headline": "Eli Lilly Dives 14% On A Shocking Obesity Setback, Sending Its Rivals Flying",
      "id": 136248816,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly stock tumbled Thursday on an unexpected setback for its obesity franchise, sending shares of its rival flying.",
      "url": "https://finnhub.io/api/news?id=caecb6949683ec8e92e01bbf681ed85e9db57d8a20394ddadc05e5862b7d3724"
    }
  },
  {
    "ts": null,
    "headline": "Stock market today: Dow slides, Nasdaq jumps to record as tariffs kick in, Trump nominates Miran to Fed board",
    "summary": "US stocks edged higher as President Trump hinted at chip tariff carveouts as sweeping duties took effect.",
    "url": "https://finnhub.io/api/news?id=1dece28f32e1a21d9f5c06b33992074306b31e3d747e03ffd39d0088d0ce0643",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754596973,
      "headline": "Stock market today: Dow slides, Nasdaq jumps to record as tariffs kick in, Trump nominates Miran to Fed board",
      "id": 136266313,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "US stocks edged higher as President Trump hinted at chip tariff carveouts as sweeping duties took effect.",
      "url": "https://finnhub.io/api/news?id=1dece28f32e1a21d9f5c06b33992074306b31e3d747e03ffd39d0088d0ce0643"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly's Share Price Sheds Some Weight: This Doesn't Mean To Pile In",
    "summary": "Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may simply want to hold for now.",
    "url": "https://finnhub.io/api/news?id=ca08b038fdbc777853dfa8665e0d6d047a108ec398a5f4add2cbd6f301247f55",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754593488,
      "headline": "Eli Lilly's Share Price Sheds Some Weight: This Doesn't Mean To Pile In",
      "id": 136262900,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/521503314/image_521503314.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly stock beats Q2 estimates with strong sales but faces competitive risks and high valuation. Here's why investors may simply want to hold for now.",
      "url": "https://finnhub.io/api/news?id=ca08b038fdbc777853dfa8665e0d6d047a108ec398a5f4add2cbd6f301247f55"
    }
  },
  {
    "ts": null,
    "headline": "Health Care Down After Eli Lilly Earnings -- Health Care Roundup",
    "summary": "Health Care Down After Eli Lilly Earnings -- Health Care Roundup",
    "url": "https://finnhub.io/api/news?id=35d50ceb653c52ef969a80f9472a9128440bd015c2f91f357d99d66fd21b730d",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754589180,
      "headline": "Health Care Down After Eli Lilly Earnings -- Health Care Roundup",
      "id": 136296162,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Health Care Down After Eli Lilly Earnings -- Health Care Roundup",
      "url": "https://finnhub.io/api/news?id=35d50ceb653c52ef969a80f9472a9128440bd015c2f91f357d99d66fd21b730d"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Dow Swings To Drop 224 Points; Nasdaq Ekes A Out A Gain",
    "summary": "Stock Market Today: Dow Swings To Drop 224 Points; Nasdaq Ekes A Out A Gain",
    "url": "https://finnhub.io/api/news?id=18ac31f5f2f2af140f26d5251d57b8a17434ced10f562ac551f62ac44972cbf0",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754584780,
      "headline": "Stock Market Today: Dow Swings To Drop 224 Points; Nasdaq Ekes A Out A Gain",
      "id": 136295850,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "Stock Market Today: Dow Swings To Drop 224 Points; Nasdaq Ekes A Out A Gain",
      "url": "https://finnhub.io/api/news?id=18ac31f5f2f2af140f26d5251d57b8a17434ced10f562ac551f62ac44972cbf0"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly’s weight-loss pill didn’t work so well, and the stock is plunging",
    "summary": "Eli Lilly’s weight-loss pill didn’t work so well, and the stock is plunging",
    "url": "https://finnhub.io/api/news?id=b14b892c37820f0ed51ee54b89ec2560e20e0a1a62ff4ddf00050577e0414909",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754584260,
      "headline": "Eli Lilly’s weight-loss pill didn’t work so well, and the stock is plunging",
      "id": 136296163,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly’s weight-loss pill didn’t work so well, and the stock is plunging",
      "url": "https://finnhub.io/api/news?id=b14b892c37820f0ed51ee54b89ec2560e20e0a1a62ff4ddf00050577e0414909"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly And Biogen (And Eisai): Muddying The Waters In Alzheimer's Disease",
    "summary": "Eli Lilly And Biogen (And Eisai): Muddying The Waters In Alzheimer's Disease",
    "url": "https://finnhub.io/api/news?id=6dde105958fe560ebdb5c8e3d41004d62882fe8e2a662ef3af62754c7884e26e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754577090,
      "headline": "Eli Lilly And Biogen (And Eisai): Muddying The Waters In Alzheimer's Disease",
      "id": 136256581,
      "image": "",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=6dde105958fe560ebdb5c8e3d41004d62882fe8e2a662ef3af62754c7884e26e"
    }
  },
  {
    "ts": null,
    "headline": "Healthcare Stocks Have Been Beaten Up. The Case for Buying Now.",
    "summary": "Healthcare Stocks Have Been Beaten Up. The Case for Buying Now.",
    "url": "https://finnhub.io/api/news?id=8d264821b08601c936b802e380ff4b2908d9a51ac5d1bbfccb9497cc16a8426e",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754454600,
      "headline": "Healthcare Stocks Have Been Beaten Up. The Case for Buying Now.",
      "id": 136252135,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Healthcare Stocks Have Been Beaten Up. The Case for Buying Now.",
      "url": "https://finnhub.io/api/news?id=8d264821b08601c936b802e380ff4b2908d9a51ac5d1bbfccb9497cc16a8426e"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Q2 Earnings: Ignore Oral Weight Loss Bombshell, This Is A Buy The Dip Moment",
    "summary": "Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY may be a buying opportunity.",
    "url": "https://finnhub.io/api/news?id=8f363360378a2f7c97f0bed1a19e3711ea97fe2d3356e9116b4bdb6536cd4f4d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754572471,
      "headline": "Eli Lilly Q2 Earnings: Ignore Oral Weight Loss Bombshell, This Is A Buy The Dip Moment",
      "id": 136251403,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2039512295/image_2039512295.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly stock dips despite strong Q2 results. Read my insights on obesity drug market dominance and why this selloff in LLY may be a buying opportunity.",
      "url": "https://finnhub.io/api/news?id=8f363360378a2f7c97f0bed1a19e3711ea97fe2d3356e9116b4bdb6536cd4f4d"
    }
  },
  {
    "ts": null,
    "headline": "Stock Market Today: Dow Futures Rise On Trump Tariff News; Apple, Nvidia Rally, Eli Lilly Plunges (Live Coverage)",
    "summary": "The Dow Jones Index rose Thursday on Trump tariff news. Eli Lilly plunged on disappointing weight-loss drug trial results.",
    "url": "https://finnhub.io/api/news?id=bb5b565d20087c9bace1fd2cb243104a7a58aff768b83da6db71aebddf693324",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754572024,
      "headline": "Stock Market Today: Dow Futures Rise On Trump Tariff News; Apple, Nvidia Rally, Eli Lilly Plunges (Live Coverage)",
      "id": 136245930,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "The Dow Jones Index rose Thursday on Trump tariff news. Eli Lilly plunged on disappointing weight-loss drug trial results.",
      "url": "https://finnhub.io/api/news?id=bb5b565d20087c9bace1fd2cb243104a7a58aff768b83da6db71aebddf693324"
    }
  },
  {
    "ts": null,
    "headline": "Lilly Skids On A Shocking Obesity Setback. Novo, Viking, Structure Surge.",
    "summary": "Eli Lilly stock tumbled Thursday on an unexpected setback for its obesity franchise, sending shares of its rival flying.",
    "url": "https://finnhub.io/api/news?id=c1b83e465798ac34944153847ed9bf6e1b1359b121cacb0eb0ed9ab7291f4598",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754571706,
      "headline": "Lilly Skids On A Shocking Obesity Setback. Novo, Viking, Structure Surge.",
      "id": 136246116,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly stock tumbled Thursday on an unexpected setback for its obesity franchise, sending shares of its rival flying.",
      "url": "https://finnhub.io/api/news?id=c1b83e465798ac34944153847ed9bf6e1b1359b121cacb0eb0ed9ab7291f4598"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Reacts: Lilly's Weight-Loss Pill Falls Short--But a New Obesity Drug War Just Began",
    "summary": "Lilly misses the Wegovy benchmark, but its oral pill could still flip the script in a $95B market",
    "url": "https://finnhub.io/api/news?id=0c9efb1f9dc670bf235cc20fe77c4fbbf0c6398047dc1f30c5c79d9aef167250",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754570168,
      "headline": "Wall Street Reacts: Lilly's Weight-Loss Pill Falls Short--But a New Obesity Drug War Just Began",
      "id": 136246117,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly misses the Wegovy benchmark, but its oral pill could still flip the script in a $95B market",
      "url": "https://finnhub.io/api/news?id=0c9efb1f9dc670bf235cc20fe77c4fbbf0c6398047dc1f30c5c79d9aef167250"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company 2025 Q2 - Results - Earnings Call Presentation",
    "summary": "The following slide deck was published by Eli Lilly and Company in conjunction with their 2025 Q2 earnings call.",
    "url": "https://finnhub.io/api/news?id=80d85f845aa5aa3e9c912cc5e6762c0170c52f689deb1a6c4f49ea7acbd390ca",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754569780,
      "headline": "Eli Lilly and Company 2025 Q2 - Results - Earnings Call Presentation",
      "id": 136249620,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "The following slide deck was published by Eli Lilly and Company in conjunction with their 2025 Q2 earnings call.",
      "url": "https://finnhub.io/api/news?id=80d85f845aa5aa3e9c912cc5e6762c0170c52f689deb1a6c4f49ea7acbd390ca"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly and Company (LLY) Q2 2025 Earnings Call Transcript",
    "summary": "Eli Lilly and Company (NYSE:LLY) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ETCompany ParticipantsDaniel M.",
    "url": "https://finnhub.io/api/news?id=2b57a4a5f6efdaa7d384d4e83e29822c1078897232b00bc0ba5420ef14ad924a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754569699,
      "headline": "Eli Lilly and Company (LLY) Q2 2025 Earnings Call Transcript",
      "id": 136249578,
      "image": "https://static.seekingalpha.com/assets/og_image_1200-29b2bfe1a595477db6826bd2126c63ac2091efb7ec76347a8e7f81ba17e3de6c.png",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Eli Lilly and Company (NYSE:LLY) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ETCompany ParticipantsDaniel M.",
      "url": "https://finnhub.io/api/news?id=2b57a4a5f6efdaa7d384d4e83e29822c1078897232b00bc0ba5420ef14ad924a"
    }
  },
  {
    "ts": null,
    "headline": "Earnings live: Eli Lilly stock slides, Toyota warns on tariffs, Warner Bros. Discovery posts surprise profit",
    "summary": "Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive surprises than negative ones.",
    "url": "https://finnhub.io/api/news?id=7eff5fbd34fb02f1826a41e2ae1dc713e0e71db82b17d75707c2227a767b9b1d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754569413,
      "headline": "Earnings live: Eli Lilly stock slides, Toyota warns on tariffs, Warner Bros. Discovery posts surprise profit",
      "id": 136246118,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Second quarter earnings season is in full swing, and the results have been largely positive so far, with more positive surprises than negative ones.",
      "url": "https://finnhub.io/api/news?id=7eff5fbd34fb02f1826a41e2ae1dc713e0e71db82b17d75707c2227a767b9b1d"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm",
    "summary": "Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm",
    "url": "https://finnhub.io/api/news?id=f438c6d83a65f7d629d1cca2f50527934ca6c3f52b4bd0f5478688aaf5c75aa4",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754569200,
      "headline": "Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm",
      "id": 136296145,
      "image": "",
      "related": "LLY",
      "source": "DowJones",
      "summary": "Eli Lilly Shares Slide as Weight-Loss Pill Results Dent Enthusiasm",
      "url": "https://finnhub.io/api/news?id=f438c6d83a65f7d629d1cca2f50527934ca6c3f52b4bd0f5478688aaf5c75aa4"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk shares jump as Eli Lilly obesity pill disappoints",
    "summary": "Investing.com -- Novo Nordisk shares surged more than 11% in premarket trading Thursday after Eli Lilly’s data on its oral obesity drug orforglipron underwhelmed investors, prompting concerns over both efficacy and tolerability.",
    "url": "https://finnhub.io/api/news?id=5dbc030e0ead837bfec899cd94650d16d3ab8d0169024d55892c95a3ec8b6252",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754569038,
      "headline": "Novo Nordisk shares jump as Eli Lilly obesity pill disappoints",
      "id": 136246119,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Investing.com -- Novo Nordisk shares surged more than 11% in premarket trading Thursday after Eli Lilly’s data on its oral obesity drug orforglipron underwhelmed investors, prompting concerns over both efficacy and tolerability.",
      "url": "https://finnhub.io/api/news?id=5dbc030e0ead837bfec899cd94650d16d3ab8d0169024d55892c95a3ec8b6252"
    }
  },
  {
    "ts": null,
    "headline": "Earnings in Focus: Market Movers",
    "summary": "Ramzan takes a look at Eli Lilly (LLY), ConocoPhilips (COP) and Warner Bros. (WBD) as U.S. markets prepare to open.",
    "url": "https://finnhub.io/api/news?id=cf49da8fae342949292724a5f8c539ed71996ad357142e507c71da1f8dd355a6",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754568840,
      "headline": "Earnings in Focus: Market Movers",
      "id": 136246120,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Ramzan takes a look at Eli Lilly (LLY), ConocoPhilips (COP) and Warner Bros. (WBD) as U.S. markets prepare to open.",
      "url": "https://finnhub.io/api/news?id=cf49da8fae342949292724a5f8c539ed71996ad357142e507c71da1f8dd355a6"
    }
  },
  {
    "ts": null,
    "headline": "5 Things to Know Before the Stock Market Opens",
    "summary": "News of the day for August 7, 2025",
    "url": "https://finnhub.io/api/news?id=9f60f5d20b8f8e491c4829897b10a10118d2d94e17685f5e5fd96ee15d015340",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754567711,
      "headline": "5 Things to Know Before the Stock Market Opens",
      "id": 136246122,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "News of the day for August 7, 2025",
      "url": "https://finnhub.io/api/news?id=9f60f5d20b8f8e491c4829897b10a10118d2d94e17685f5e5fd96ee15d015340"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly (LLY) Q2 Earnings and Revenues Surpass Estimates",
    "summary": "Lilly (LLY) delivered earnings and revenue surprises of +12.48% and +5.48%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
    "url": "https://finnhub.io/api/news?id=e8f175b2f6387f2adc96bb9b12b3d9073f1c469c333e8d99a1ccb5d6d8579467",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754567702,
      "headline": "Eli Lilly (LLY) Q2 Earnings and Revenues Surpass Estimates",
      "id": 136246123,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Lilly (LLY) delivered earnings and revenue surprises of +12.48% and +5.48%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?",
      "url": "https://finnhub.io/api/news?id=e8f175b2f6387f2adc96bb9b12b3d9073f1c469c333e8d99a1ccb5d6d8579467"
    }
  },
  {
    "ts": null,
    "headline": "Danish drugmakers jump as Eli Lilly's weight-loss pill data disappoints",
    "summary": "(Reuters) -Shares in Novo Nordisk rose as much as 14% on Thursday after trial data from Eli Lilly's experimental weight-loss pill fell short of expectations, boosting investor confidence in the Danish drugmaker's market-leading obesity treatment.  The market had anticipated Eli Lilly's orforglipron pill to become a strong competitor to Novo's weight-loss drugs, Kepler Cheuvreux analyst David Evans said in an emailed comment.",
    "url": "https://finnhub.io/api/news?id=dea0071646028a18eb1fc257e16e54ed9869dfa103494cf78473b4a3167725d3",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754567415,
      "headline": "Danish drugmakers jump as Eli Lilly's weight-loss pill data disappoints",
      "id": 136246124,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Reuters) -Shares in Novo Nordisk rose as much as 14% on Thursday after trial data from Eli Lilly's experimental weight-loss pill fell short of expectations, boosting investor confidence in the Danish drugmaker's market-leading obesity treatment.  The market had anticipated Eli Lilly's orforglipron pill to become a strong competitor to Novo's weight-loss drugs, Kepler Cheuvreux analyst David Evans said in an emailed comment.",
      "url": "https://finnhub.io/api/news?id=dea0071646028a18eb1fc257e16e54ed9869dfa103494cf78473b4a3167725d3"
    }
  },
  {
    "ts": null,
    "headline": "Stocks Gain Pre-Bell as Trump's Sweeping New Tariffs Take Effect; Investors Assess Apple's $600 Billion US Investment Plan",
    "summary": "US equity markets were tracking in the green before the opening bell Thursday as President Donald Tr",
    "url": "https://finnhub.io/api/news?id=ab335e9f5c45df39939e76712e8890b1230f6bde44a9b14e64cd9b19ed800538",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754567197,
      "headline": "Stocks Gain Pre-Bell as Trump's Sweeping New Tariffs Take Effect; Investors Assess Apple's $600 Billion US Investment Plan",
      "id": 136245984,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "US equity markets were tracking in the green before the opening bell Thursday as President Donald Tr",
      "url": "https://finnhub.io/api/news?id=ab335e9f5c45df39939e76712e8890b1230f6bde44a9b14e64cd9b19ed800538"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly Stock Dives Drops After Earnings Beat. Here’s Why.",
    "summary": "Eli Lilly  stock tumbled after it released the results for an experimental weight-loss pill study and reported a beat-and-raise quarter early Thursday.  The medicine, Orforglipron, resulted in a weight reduction of on average 12.4% over 72 weeks in adults with obesity, Lilly said in a statement.  Adjusted earnings per share (EPS) came in at $6.31 on sales of $15.6 billion in the quarter, beating expectations of $5.60 a share on sales of $14.7 billion, according to FactSet.",
    "url": "https://finnhub.io/api/news?id=7f9a172e215b9bf2d327265754e8bd50efbe959ab318dae915451d257e6de50e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754566680,
      "headline": "Eli Lilly Stock Dives Drops After Earnings Beat. Here’s Why.",
      "id": 136246126,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly  stock tumbled after it released the results for an experimental weight-loss pill study and reported a beat-and-raise quarter early Thursday.  The medicine, Orforglipron, resulted in a weight reduction of on average 12.4% over 72 weeks in adults with obesity, Lilly said in a statement.  Adjusted earnings per share (EPS) came in at $6.31 on sales of $15.6 billion in the quarter, beating expectations of $5.60 a share on sales of $14.7 billion, according to FactSet.",
      "url": "https://finnhub.io/api/news?id=7f9a172e215b9bf2d327265754e8bd50efbe959ab318dae915451d257e6de50e"
    }
  },
  {
    "ts": null,
    "headline": "Wall Street Lunch: Lilly's Strong Q2 Results Overshadowed By Weight Loss Drug Data",
    "summary": "Despite reporting better-than-expected Q2 results, Eli Lilly is under pressure amid concerns over late-stage trial data for the companyâs oral weight loss drug orforglipron.",
    "url": "https://finnhub.io/api/news?id=6cd0970c482462add37d5f36259e83fcabb021f87b58542185f6b4d290811b4f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754565829,
      "headline": "Wall Street Lunch: Lilly's Strong Q2 Results Overshadowed By Weight Loss Drug Data",
      "id": 136249319,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1411734128/image_1411734128.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Despite reporting better-than-expected Q2 results, Eli Lilly is under pressure amid concerns over late-stage trial data for the companyâs oral weight loss drug orforglipron.",
      "url": "https://finnhub.io/api/news?id=6cd0970c482462add37d5f36259e83fcabb021f87b58542185f6b4d290811b4f"
    }
  },
  {
    "ts": null,
    "headline": "Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline",
    "summary": "BOSTON, August 07, 2025--Strand Therapeutics raised a $153 million Series B to develop programmable mRNA therapeutics and reshape how we treat disease -- starting with cancer.",
    "url": "https://finnhub.io/api/news?id=a8a8d47a748e048c7a539f2a37d0b84ced97226aa654acc9058a5676b3da4dec",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754565300,
      "headline": "Strand Therapeutics Raises $153 Million Series B Financing to Further Advance Programmable mRNA Therapeutic Pipeline",
      "id": 136246127,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "BOSTON, August 07, 2025--Strand Therapeutics raised a $153 million Series B to develop programmable mRNA therapeutics and reshape how we treat disease -- starting with cancer.",
      "url": "https://finnhub.io/api/news?id=a8a8d47a748e048c7a539f2a37d0b84ced97226aa654acc9058a5676b3da4dec"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly second quarter earnings beat on strong GLP-1 sales, but stock dives on GLP-1 pill trial results",
    "summary": "Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall Street.",
    "url": "https://finnhub.io/api/news?id=7ac127bc2dc9ae144d21a8ceaa0d91a5b41459e1c2e56151d521aa40623f47a8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754564490,
      "headline": "Eli Lilly second quarter earnings beat on strong GLP-1 sales, but stock dives on GLP-1 pill trial results",
      "id": 136246128,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly reported second quarter earnings Thursday, a day after competitor Novo Nordisk missed earnings estimates by Wall Street.",
      "url": "https://finnhub.io/api/news?id=7ac127bc2dc9ae144d21a8ceaa0d91a5b41459e1c2e56151d521aa40623f47a8"
    }
  },
  {
    "ts": null,
    "headline": "ProQR Announces Second Quarter 2025 Operating and Financial Results",
    "summary": "Submitted CTA for lead program AX-0810, targeting NTCP for cholestatic diseasesAdvancing AX-2402 program toward clinical candidate selection, targeting MECP2 (R270X) for Rett SyndromeHosting fall Analyst and Investor Event (virtual), featuring detailed AX-0810 Phase 1 trial design and 2025 data expectations, plus updates across differentiated liver and CNS pipeline€ 119.8 million cash and cash equivalents as of end Q2 – providing runway into mid-2027, not including additional potential milestone",
    "url": "https://finnhub.io/api/news?id=1ec1dbac8deae31480e0f6813366b0f7d54ead3e5591fea14eb6dcd9b2526c84",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754564400,
      "headline": "ProQR Announces Second Quarter 2025 Operating and Financial Results",
      "id": 136246129,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Submitted CTA for lead program AX-0810, targeting NTCP for cholestatic diseasesAdvancing AX-2402 program toward clinical candidate selection, targeting MECP2 (R270X) for Rett SyndromeHosting fall Analyst and Investor Event (virtual), featuring detailed AX-0810 Phase 1 trial design and 2025 data expectations, plus updates across differentiated liver and CNS pipeline€ 119.8 million cash and cash equivalents as of end Q2 – providing runway into mid-2027, not including additional potential milestone",
      "url": "https://finnhub.io/api/news?id=1ec1dbac8deae31480e0f6813366b0f7d54ead3e5591fea14eb6dcd9b2526c84"
    }
  },
  {
    "ts": null,
    "headline": "Lilly: Q2 Earnings Snapshot",
    "summary": "Earnings, adjusted for one-time gains and costs, came to $6.31 per share. The results surpassed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $5.61 per share.",
    "url": "https://finnhub.io/api/news?id=30da62f126ef61e0060078535bd77a4aa653a368da7c56aeb640096b4e12cf7c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754564037,
      "headline": "Lilly: Q2 Earnings Snapshot",
      "id": 136246130,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Earnings, adjusted for one-time gains and costs, came to $6.31 per share. The results surpassed Wall Street expectations. The average estimate of nine analysts surveyed by Zacks Investment Research was for earnings of $5.61 per share.",
      "url": "https://finnhub.io/api/news?id=30da62f126ef61e0060078535bd77a4aa653a368da7c56aeb640096b4e12cf7c"
    }
  },
  {
    "ts": null,
    "headline": "Lilly raises full-year earnings forecasts on surging demand for weight-loss drug",
    "summary": "(Reuters) -Eli Lilly raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster weight-loss drug, Zepbound, as it targets new markets and looks to grab more share from Novo Nordisk's Wegovy.  However, shares of the U.S. drugmaker fell over 10% to $671.54 in premarket trading after data from its oral weight loss drug, orforglipron, disappointed investors.  Orforglipron helped patients lose 12.4% of their weight on average after 72 weeks, less than the 14.9% weight loss seen in a previous trial of Novo's Wegovy over 68 weeks and below what analysts were expecting.",
    "url": "https://finnhub.io/api/news?id=0fd79c58abb89ac6acff284483a5e688babac5a98231909ebc360fab447b7a76",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754563920,
      "headline": "Lilly raises full-year earnings forecasts on surging demand for weight-loss drug",
      "id": 136246131,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "(Reuters) -Eli Lilly raised its full-year profit and sales forecast on Thursday, betting on surging demand for its blockbuster weight-loss drug, Zepbound, as it targets new markets and looks to grab more share from Novo Nordisk's Wegovy.  However, shares of the U.S. drugmaker fell over 10% to $671.54 in premarket trading after data from its oral weight loss drug, orforglipron, disappointed investors.  Orforglipron helped patients lose 12.4% of their weight on average after 72 weeks, less than the 14.9% weight loss seen in a previous trial of Novo's Wegovy over 68 weeks and below what analysts were expecting.",
      "url": "https://finnhub.io/api/news?id=0fd79c58abb89ac6acff284483a5e688babac5a98231909ebc360fab447b7a76"
    }
  },
  {
    "ts": null,
    "headline": "These Stocks Are Moving the Most Today: Eli Lilly, Fortinet, AppLovin, Sunrun, Airbnb, Duolingo, and More",
    "summary": "A slew or company results were causing big market moves ahead of the opening bell Thursday, and for many, earnings-beat wasn’t enough to prevent a selloff.",
    "url": "https://finnhub.io/api/news?id=5894614111540c9b93eb67c91d0c7cc02d28feee184f7016fab13c0026115e07",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754563500,
      "headline": "These Stocks Are Moving the Most Today: Eli Lilly, Fortinet, AppLovin, Sunrun, Airbnb, Duolingo, and More",
      "id": 136246133,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "A slew or company results were causing big market moves ahead of the opening bell Thursday, and for many, earnings-beat wasn’t enough to prevent a selloff.",
      "url": "https://finnhub.io/api/news?id=5894614111540c9b93eb67c91d0c7cc02d28feee184f7016fab13c0026115e07"
    }
  },
  {
    "ts": null,
    "headline": "Lilly reports second-quarter 2025 financial results and raises guidance",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced its financial results for the second quarter of 2025.",
    "url": "https://finnhub.io/api/news?id=fe3f592a0af03cb47171831b04f58da109239db5c08cc73542fe6173bf4cf793",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754563500,
      "headline": "Lilly reports second-quarter 2025 financial results and raises guidance",
      "id": 136246132,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced its financial results for the second quarter of 2025.",
      "url": "https://finnhub.io/api/news?id=fe3f592a0af03cb47171831b04f58da109239db5c08cc73542fe6173bf4cf793"
    }
  },
  {
    "ts": null,
    "headline": "Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity",
    "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ATTAIN-1 trial, evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, in 3,127 adults with obesity, or overweight with a weight-related medical problem and without diabetes. At 72 weeks, all three doses of orforglipron, met the primary endpoint and all key secondary endpoints compared to placebo, delivering clinically meaningful weight loss as an adjunct to a h",
    "url": "https://finnhub.io/api/news?id=d243657c8e95615544c943feb3447ce481e8a5395172feabd56c218f247da202",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754562300,
      "headline": "Lilly's oral GLP-1, orforglipron, delivers weight loss of up to an average of 27.3 lbs in first of two pivotal Phase 3 trials in adults with obesity",
      "id": 136246134,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "LLY",
      "source": "Yahoo",
      "summary": "Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the Phase 3 ATTAIN-1 trial, evaluating orforglipron, an investigational oral glucagon-like peptide-1 (GLP-1) receptor agonist, in 3,127 adults with obesity, or overweight with a weight-related medical problem and without diabetes. At 72 weeks, all three doses of orforglipron, met the primary endpoint and all key secondary endpoints compared to placebo, delivering clinically meaningful weight loss as an adjunct to a h",
      "url": "https://finnhub.io/api/news?id=d243657c8e95615544c943feb3447ce481e8a5395172feabd56c218f247da202"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly’s Weight Loss Pill Doesn’t Work as Well as Investors Hoped. The Obesity Trade Is Wavering Again.",
    "summary": "Eli Lilly’s Weight Loss Pill Doesn’t Work as Well as Investors Hoped. The Obesity Trade Is Wavering Again.",
    "url": "https://finnhub.io/api/news?id=97839baeeadcfe7bd00cc854258552ad7ae2bd0a650866787c9d7d26516dbe18",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754562240,
      "headline": "Eli Lilly’s Weight Loss Pill Doesn’t Work as Well as Investors Hoped. The Obesity Trade Is Wavering Again.",
      "id": 136296166,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Eli Lilly’s Weight Loss Pill Doesn’t Work as Well as Investors Hoped. The Obesity Trade Is Wavering Again.",
      "url": "https://finnhub.io/api/news?id=97839baeeadcfe7bd00cc854258552ad7ae2bd0a650866787c9d7d26516dbe18"
    }
  },
  {
    "ts": null,
    "headline": "Eli Lilly: targets raised for 2025",
    "summary": "In its quarterly report, Eli Lilly said that it is raising its adjusted EPS target range for FY 2025 to between $21.75 and $23, up from a previous forecast of $20.78 to $22.28. However, NB: after...",
    "url": "https://finnhub.io/api/news?id=5799b352e43055b863f2451a262abff4031f26ef2688bd9a6735fa166f3daf7b",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754553926,
      "headline": "Eli Lilly: targets raised for 2025",
      "id": 136245611,
      "image": "",
      "related": "LLY",
      "source": "Finnhub",
      "summary": "In its quarterly report, Eli Lilly said that it is raising its adjusted EPS target range for FY 2025 to between $21.75 and $23, up from a previous forecast of $20.78 to $22.28. However, NB: after...",
      "url": "https://finnhub.io/api/news?id=5799b352e43055b863f2451a262abff4031f26ef2688bd9a6735fa166f3daf7b"
    }
  },
  {
    "ts": null,
    "headline": "Novo Nordisk: More Pain On The Horizon",
    "summary": "Novo Nordisk faces slowing revenue growth, weak Q2 2025 results, and a more conservative outlook. Read why I rate NVO stock a Sell.",
    "url": "https://finnhub.io/api/news?id=3ba61bedb4aa6b93de9fac91cadb508b169aaecf76952a960bd75170d07ced51",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754546041,
      "headline": "Novo Nordisk: More Pain On The Horizon",
      "id": 136245151,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2158305433/image_2158305433.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Novo Nordisk faces slowing revenue growth, weak Q2 2025 results, and a more conservative outlook. Read why I rate NVO stock a Sell.",
      "url": "https://finnhub.io/api/news?id=3ba61bedb4aa6b93de9fac91cadb508b169aaecf76952a960bd75170d07ced51"
    }
  },
  {
    "ts": null,
    "headline": "From Nvidia's Surge To Apple's Slip: 6 Stocks That Defined Ithaka's Quarter",
    "summary": "Ithaka Group unpacks Q2âs portfolio drivers - from AI surges to tariff shocks. See which stocks moved the needle and what it means for investors.",
    "url": "https://finnhub.io/api/news?id=e652ef01177522dbfd8be18717a40bc1430b8ea565e2261105fcbf35f9791ca3",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754545500,
      "headline": "From Nvidia's Surge To Apple's Slip: 6 Stocks That Defined Ithaka's Quarter",
      "id": 136245122,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1159051360/image_1159051360.jpg?io=getty-c-w1536",
      "related": "LLY",
      "source": "SeekingAlpha",
      "summary": "Ithaka Group unpacks Q2âs portfolio drivers - from AI surges to tariff shocks. See which stocks moved the needle and what it means for investors.",
      "url": "https://finnhub.io/api/news?id=e652ef01177522dbfd8be18717a40bc1430b8ea565e2261105fcbf35f9791ca3"
    }
  },
  {
    "ts": null,
    "headline": "Oil major ConocoPhillips headlines earnings",
    "summary": "Oil major ConocoPhillips headlines earnings",
    "url": "https://finnhub.io/api/news?id=5b86d0360846aa882b28bca9481b47fbed5aa17f63ed18d7b94a4e1747d72d32",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1754544878,
      "headline": "Oil major ConocoPhillips headlines earnings",
      "id": 136258333,
      "image": "",
      "related": "LLY",
      "source": "MarketWatch",
      "summary": "Oil major ConocoPhillips headlines earnings",
      "url": "https://finnhub.io/api/news?id=5b86d0360846aa882b28bca9481b47fbed5aa17f63ed18d7b94a4e1747d72d32"
    }
  }
]